Citations Appearing in 1993

  1. Cook, C.E., A.R. Jeffcoat, J.M. Hill, D.E. Pugh, P.K. Patetta, B.M. Sadler, W.R. White and M. Perezreyes. Pharmacokinetics of methamphetamine self administered to human subjects by smoking S-(+)-methamphetamine hydrochloride. Drug Metabolism and Disposition 21:717-723, 1993.
  2. D’Argenio, D.Z. and J.H. Rodman. Targeting the systemic exposure of Teniposide in the population and the individual using a stochastic therapeutic objective. Journal of Pharmacokinetics and Biopharmaceutics 21:223-251, 1993.
  3. Demidecki, A.J., L.E. Williams, J.Y.C. Wong, B.W. Wessels, E.D. Yorke, M. Strandh and S.E. Strand. Considerations on the calibration of small thermoluminescent dosimeters used for measurement of beta particle absorbed doses in liquid environments. Medical Physics 20:1079-1087, 1993.
  4. Demuria, D., A. Forrest, J. Rich, J.M. Scavone, L.G. Cohen and P.H. Kazanjian. Pharmacokinetics and bioavailability of Fluconazole in patients with AIDS. Antimicrobial Agents and Chemotherapy 37:2187-2192, 1993.
  5. Drusano, G.L., D.E. Johnson, M. Rosen and H.C. Standiford. Pharmacodynamics of a Fluoroquinolone antimicrobial agent in a neutropenic rat model of pseudomonas sepsis. Antimicrobial Agents and Chemotherapy 37:483-490, 1993.
  6. Eisenberg, M.A., L.M. Reyno, D.I. Jodrell, V.J. Sinibaldi, K.H. Tkaczuk, R. Sridhara, E.G. Zuhowski, M.H. Lowitt, S.C. Jacobs and M.G. Egorin. Suramin, an active drug for prostate cancer: interim observations in a phase I trial. Journal of the National Cancer Institute 85:611-621, 1993.
  7. Erlichman, C., M. Moore, J.J. Thiessen, I.G. Kerr, S. Walker, P. Goodman, G. Bjarnason, C. Deangelis and P. Bunting. Phase I pharmacokinetic study of cyclosporine A combined with doxorubicin. Cancer Research 53:4837-4842, 1993.
  8. Flogel, C.M., D.S. Ward, D.R. Wada and J.W. Ritter. The effects of large dose Flumazenil on Midazolam induced ventilatory depression. Anesthesia Anelgesia 77: 1207-1214, 1993.
  9. Forrest, A., C.H. Ballow, D.E. Nix, M.C. Birmingham and J.J. Schentag. Development of a population pharmacokinetic model and optimal sampling strategies for intravenous ciprofloxacin. Antimicrobial Agents and Chemotherapy37:1065-1072, 1993.
  10. Forrest, A., D.E. Nix, C.H. Ballow, T.F. Goss, M.C. Birmingham and J.J. Schentag. Pharmacodynamics of intravenous Ciprofloxacin in seriously ill patients. Antimicrobial Agents and Chemotherapy 37:1073-1081, 1993.
  11. Harpalani, A.D., S.W. Snyder, B. Subramanyam, M.J. Egorin and P.S. Callery. Alkylamides as inducers of human leukemia cell differentiation: a quantitative structure-activity relationship study using comparative molecular field analysis. Cancer Research 53:766-771, 1993.
  12. Hess, M.M., B.A. Boucher, S.C. Laizure, R.C. Stevens, P.L. Sanders, S.W. Janning, M.A. Croce and T.C. Fabian. Trimethoprim sulfamethoxazole pharmacokinetics in trauma patients. Pharmacotherapy 13:602-606, 1993.
  13. Hutson, P.R., K. Tutsch, D. Spriggs, M. Christian, R. Rago, R. Mutch and G. Wilding. Evidence of an Absorption phase after short intravenous suramin infusions. Cancer Chemotherapy and Pharmacology 31:495-499, 1993.
  14. Jelliffe, R.W., A. Schumitzky, M. Vanguilder, M. Liu, L. Hu, P. Maire, P. Gomis, X. Barbaut and B. Tahani. Individualizing drug dosage regimens roles of population pharmacokinetic and dynamic models, Bayesian fitting, and adaptive control. Therapeutic Drug Monitoring 15:380-393, 1993.
  15. Kayne, L.H., D.Z. D’Argenio, J.H. Meyer, M.S. Hu, N. Jamgotchian and D.B.N. Lee. Analysis of segmental phosphate absorption in intact rats – a compartmental analysis approach. Journal of Clinical Investigation 91:915-922, 1993.
  16. Kearns, C.M., W.C. Wang, N. Stute, J.N. Ihle and W.E. Evans. Disposition of recombinant human granulocyte colony stimulating factor in children with severe chronic neutropenia. Journal of Pediatrics 123:471-479, 1993.
  17. Koren, G., S. Weitzman, J. Klein and G. Moselhy. Comparison of Carboplatin pharmacokinetics between an anephric child and 2 children with normal renal function. Medical and Pediatric Oncology 21:368-372, 1993.
  18. Kort, J.J., J.A. Bilello, G. Bauer and G.L. Drusano. Preclinical evaluation of antiviral activity and toxicity of Abbott-A77003, an inhibitor of the human immunodeficiency virus type-1 protease. Antimicrobial Agents and Chemotherapy 37:115-119, 1993.
  19. Lopez, F.G., C.F. Lastra and H.P. Kuemmerle. Pharmacokinetic study of salicylic acid after oral and intramuscular administration of Imidazole 2-Hydroxybenzoate in man. International Journal of Experimental and Chemotherapy 6:51-58, 1993.
  20. Mackay, M.V., J.S. Burson, J. Martinezlanao and A. Dominguezgil. Drug dosage in end-stage renal disease (ESRD) patients undergoing hemodialysis – a predictive study based on a microcomputer program. Clinical Pharmacokinetics 25:243-257, 1993.
  21. Marina, N.M., J.H. Rodman, S.J. Shema, L.C. Bowman, E. Douglass, W.L. Furman, V.M. Santana, M. Hudson, J. Wilimas, W. Meyer, T. Madden and C. Pratt. Phase I study of escalating targeted doses of Carboplatin combined with Ifosfamide and Etoposide in children with relapsed solid tumors. Journal of Clinical Oncology11:287- 293, 1993.
  22. Mestorino, N., M.F. Landoni, M. Alt and J.O. Errecalde. The pharmacokinetics of thiamphenicol in lactating cows. Veterinary Research Communications 17:295-303, 1993.
  23. Moore, M.J., P. Bunting, S.H. Yuan and J.J Thiessen. Development and validation of a limited sampling strategy for 5-Fluorouracil given by bolus intravenous administration. Therapeutic Drug Monitoring 15:394-399, 1993.
  24. Murry, D.J., T. Sandlund, L.M. Stricklin and J.H. Rodman. Pharmacokinetics and acute renal effects of continuous infusion Carboplatin in pediatric patients with newly diagnosed large cell lymphoma. Clinical Pharmacology and Therapeutics 54:374-380, 1993.
  25. Pennie, R.A., G. Koren and C. Crevoisier. Steady state pharmacokinetics of Mefloquine in long term travelers. Transactions of the Royal Society of Tropical Medicine and Hygiene 87:459-462, 1993.
  26. Piotrovskij, V.K., Z. Kallay, M. Gajdos, M. Gerykova and T. Trnovec. The use of a nonlinear absorption model in the study of ascorbic acid bioavailability in man. Biopharmaceutics and Drug Disposition 14:429-442, 1993.
  27. Rodman, J.H., W.L. Furman, M. Sunderland and G.K. Rivera. Escalating Teniposide systemic exposure to increase dose intensity for pediatric cancer patients. Journal of Clinical Oncology 11:554-560, 1993.
  28. Rodman, J.H., D.C. Maneval, L. Magill and M. Sunderland. Measurement of Tc-99m DTPA serum clearance for estimation of GFR in pediatric cancer patients. Pharmacotherapy 13:27-36, 1993.
  29. Rodrigues, M.L., B. Snedecor, C. Chen, W.L.T. Wong, S. Garg, G.S. Blank, D. Maneval and P. Carter. Engineering Fab fragments for efficient F(Ab)(2) formation in escherichia coli and for improved in-vivo stability. Journal of Immunology 151:6954- 6961, 1993.
  30. Schwinghammer, T.L., R.A. Fleming, C.S. Rosenfeld, D. Przepiorka, R.K. Shadduck, E.J. Bloom and C.F. Stewart. Disposition of total and unbound Etoposide following high dose therapy. Cancer Chemotherapy and Pharmacology 32:273-278, 1993.
  31. Smith, D.C., D.I. Jodrell, M.J. Egorin, R.M. Ambinder, E.G. Zuhowski, W. Kreis, P.G. Ellis and D.L. Trump. Phase II trial and pharmacokinetic assessment of intravenous Melphalan in patients with advanced prostate cancer. Cancer Chemotherapy and Pharmacology 31:363-368, 1993.
  32. Stobie, S., J. Tyberg, D. Matsui, D. Fernandes, J. Klein, N. Olivieri, Y. Bentur and G. Koren. Comparison of the pharmacokinetics of 1,2-Dimethyl-3-Hydroxypyrid-4-one (L1) in healthy volunteers, with and without coadministration of ferrous sulfate, to thalassemia patients. International Journal of Clinical Pharmacology and Therapeutics 31:602-605, 1993.
  33. Tod, M., O. Petitjean and P. Nicolas. Evaluation of optimal sampling theory in bioequivalence studies. Therapie 48:7-13, 1993.
  34. Wilimas, J.A., P.M. Flynn, S. Harris, S. Day, R. Smith, P.J. Chesney, J.H. Rodman, J. Equiquren and W. Wang. Safety and effectiveness of out-patient treatment with Ceftriaxone for febrile children with sickle cell disease: a randomized study. New England Journal of Medicine 329:472-476, 1993.
  35. Xu, X., P. Selick and K.S. Pang. Nonlinear protein binding and enzyme heterogeneity – effects on hepatic drug removal. Journal of Pharmacokinetics and Biopharmaceutics 21:43-74, 1993.
  36. Zhang, R.W., T.P. Liu, S.J. Soong and R.B. Diasio. A mathematical model of the kinetics and tissue distribution of 2-Fluoro-Beta-Alanine, the major catabolite of 5- Fluorouracil. Biochemical Pharmacology 45:2063-2069, 1993.